Why Is Blood Cancer Focused Syros Pharmaceuticals Stock Soaring Today? – Syros Pharmaceuticals (NASDAQ:SYRS)


Syros Pharmaceuticals Inc. recently released initial data from its ongoing SELECT-AML-1 Phase 2 trial of tamibarotene in combination with venetoclax and azacitidine. This trial is being conducted in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.

In December 2022, Syros reported data from the safety lead-in portion of SELECT-AML-1, where five out of six response evaluable patients achieved CR/CRi, which is a significant response rate.

As of November 13, 2023, a total of 23 newly diagnosed unfit AML patients positive for RARA overexpression had enrolled in the trial. The primary endpoint, which is the CR/CRi rate, was 100% among response evaluable patients treated with the combination of tamibarotene, venetoclax, and azacitidine, compared to 70% of patients treated with the control (venetoclax and azacitidine alone).

Among the response evaluable patients, 78% treated with the combination achieved a CR, and 22% achieved a CRi. In contrast, only 30% of patients treated with the control achieved a CR, and 40% achieved a CRi.

The median time to CR/CRi response was shorter for patients treated with the combination of tamibarotene, venetoclax, and azacitidine compared to those treated with the control. Patients in the triplet arm reached CR/CRi by the end of cycle one, while patients in the doublet control arm took longer to achieve the same response.

Syros Pharmaceuticals Inc. continues to enroll patients in the SELECT-AML-1 trial and plans to report updated data in 2024. Additionally, the company is evaluating tamibarotene in combination with azacitidine in the SELECT-MDS-1 Phase 3 trial for newly diagnosed higher-risk myelodysplastic syndrome patients with RARA gene overexpression. Patient enrollment for SELECT-MDS-1 is expected to be completed in Q1 of 2024, and pivotal CR data will be reported by mid-Q4 of 2024.

Syros Pharmaceuticals Inc. has seen a significant increase in its stock price, with shares up 46.50% at $4.13 on the last check Wednesday.

In conclusion, the initial data from the ongoing SELECT-AML-1 trial shows promising results for the combination of tamibarotene, venetoclax, and azacitidine in newly diagnosed, unfit AML patients with RARA gene overexpression. These findings provide hope for improved treatment options and outcomes for patients with this aggressive form of leukemia.

Leave a Reply

Your email address will not be published. Required fields are marked *